WALTHAM, Mass. — August 21, 2025 — BiotechReporter.news — Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at $0.52 per share. Pre-funded warrants to purchase 21,342,442 shares of its common stock were offered at $0.5199 per pre-funded warrant. Gross proceeds are expected to be approximately $50.0 million before deductions.
Invivyd has granted underwriters an option to purchase up to an additional 14,423,076 shares of common stock at the public offering price, less discounts. The offering is expected to close around August 22, 2025.
Invivyd plans to use the net proceeds for trial protocol development, the VYD2311 clinical program, research and development related to its pipeline programs such as RSV and measles, and the SPEAR Study Group efforts, as well as for working capital and other corporate purposes.
Cantor is acting as sole book-running manager.
Media Relations: (781) 208-1747, media@invivyd.com; Investor Relations: (781) 208-1747, investors@invivyd.com
Source: Invivyd, Inc.
